Quantitative digital pathology reveals association of cell-specific PNPLA3 transcription with NAFLD disease activity

Bynvant Sandhu; Maria C Perez Matos; Stephanie Tran; Alexander Zhong; Eva Csizmadia; Misung Kim; Mark A Herman; Imad Nasser; Michelle Lai; Z Gordon Jiang

doi:10.1016/j.jhepr.2019.05.007

Quantitative digital pathology reveals association of cell-specific PNPLA3 transcription with NAFLD disease activity

JHEP Rep. 2019 Jun 8;1(3):199-202. doi: 10.1016/j.jhepr.2019.05.007. eCollection 2019 Sep.

Authors

Affiliations

¹ Division of Gastroenterology & Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
² Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
³ Division of Endocrinology, Duke University Medical Center, Durham, NC.
⁴ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard Medical School, Boston, MA.

Abstract

Background & aims: The I148M variant (rs738409) in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is by far the most important genetic determinant of non-alcoholic fatty liver disease (NAFLD). However, in the context of NAFLD, the transcriptional regulation of PNPLA3 in human liver cells is not known. In this study, we aimed to define the relationship between PNPLA3 transcription and disease characteristics of human NAFLD.

Methods: The abundance of PNPLA3 and collagen 1α (COL1α) transcripts was quantified in situ at single-cell resolution using RNAscope® in 87 patients with NAFLD. We examined the association of PNPLA3 and COL1α transcript levels with NAFLD disease severity, defined by histology.

Results: While the majority of PNPLA3 transcripts were found in hepatocytes, approximately 7% of PNPLA3-positive cells co-express COL1α, representing activated myofibroblasts. There is no association between the rs738409 genotype and the level of PNPLA3 transcript. The overall PNPLA3 transcript abundance is lower in zone 1 hepatocytes, patients with higher body mass index, and those with advanced liver fibrosis. The negative association between the PNPLA3 transcript levels and liver fibrosis is largely driven by COL1α-positive cells. A significant proportion of PNPLA3 mRNA is seen in the nucleus. The cytoplasmic-to-nuclear PNPLA3 mRNA ratio is inversely associated with NAFLD disease activity.

Conclusions: PNPLA3 transcript abundance and nuclear-to-cytoplasmic translocation are negatively associated with hepatic steatosis and NAFLD disease activity, while its abundance in activated myofibroblasts is inversely associated with the stage of liver fibrosis.

Lay summary: A genetic variant in patatin-like phospholipase domain-containing protein 3 (or PNPLA3) is the most important genetic determinant of non-alcoholic fatty liver disease (NAFLD). However, it is not known how transcriptional regulation of the PNPLA3 gene contributes to the disease characteristics of human NAFLD. Herein, we show that the mRNA levels of PNPLA3, particularly in the cytoplasm, are negatively associated with the severity of NAFLD in humans.

Keywords: COL1α; NASH; Non-alcoholic fatty liver disease; RNAscope; collagen 1α; liver fibrosis; non-alcoholic steatohepatitis; patatin-like phospholipase domain-containing protein 3.